Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lewis

Showing results (1251-1260 of 1,275) with videos related to

Pageof 128
Sort By:
Journal of the American College of Cardiology|September 2, 2025
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTORFaiez Zannad, Yogesh N V Reddy, Irina Barash, et al.
European Journal of Heart Failure|April 12, 2023
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trialJawad H Butt, Brian L Claggett, Zi M Miao, et al.
American Journal of Human Genetics|April 30, 2026
Navigating data sharing in researchAnna C F Lewis, Ellen W Clayton, Hana Bangash, et al.
Public Health Genomics|May 29, 2026
Imagining Genomics and Population Health in 2050: Anticipating Future Research, Policy, and Governance NeedsBartha Maria Knoppers, Yann Joly, Ma Apos N H Zawati, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JAMA|August 14, 2024
Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical TrialGervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, et al.
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
American Journal of Human Genetics|April 30, 2024
Managing differential performance of polygenic risk scores across groups: Real-world experience of the eMERGE NetworkAnna C F Lewis, Rex L Chisholm, John J Connolly, et al.
American Journal of Obstetrics and Gynecology|August 12, 2020
Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm PreeclampsiaMichael J Paidas, Allan T N Tita, George A Macones, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
Pageof 128

Showing results (1251-1260 of 1,275) with videos related to

Sort By:
Pageof 128
Journal of the American College of Cardiology|September 2, 2025
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTORFaiez Zannad, Yogesh N V Reddy, Irina Barash, et al.
European Journal of Heart Failure|April 12, 2023
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trialJawad H Butt, Brian L Claggett, Zi M Miao, et al.
American Journal of Human Genetics|April 30, 2026
Navigating data sharing in researchAnna C F Lewis, Ellen W Clayton, Hana Bangash, et al.
Public Health Genomics|May 29, 2026
Imagining Genomics and Population Health in 2050: Anticipating Future Research, Policy, and Governance NeedsBartha Maria Knoppers, Yann Joly, Ma Apos N H Zawati, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JAMA|August 14, 2024
Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical TrialGervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, et al.
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
American Journal of Human Genetics|April 30, 2024
Managing differential performance of polygenic risk scores across groups: Real-world experience of the eMERGE NetworkAnna C F Lewis, Rex L Chisholm, John J Connolly, et al.
American Journal of Obstetrics and Gynecology|August 12, 2020
Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm PreeclampsiaMichael J Paidas, Allan T N Tita, George A Macones, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
Pageof 128